T cell Ig mucin 1 (TIM-1) plays an important role in regulating immune responses in autoimmune and asthma models, and it is expressed on both Th1 and Th2 cells. Using an antagonistic TIM-1–specific antibody, we studied the role of TIM-1 in alloimmunity. A short course of TIM-1–specific antibody monotherapy prolonged survival of fully MHC-mismatched vascularized mouse cardiac allografts. This prolongation was associated with inhibition of alloreactive Th1 responses and preservation of Th2 responses. TIM-1–specific antibody treatment was more effective in Th1-type cytokine–deficient Stat4–/– recipients as compared with Th2-type cytokine–deficient Stat6–/– recipients. Subtherapeutic doses of rapamycin plus TIM-1–specific antibody resulted in allograft acceptance and prevented the development of chronic allograft vasculopathy. Allograft survival via this treatment was accompanied by a Th1- to Th2-type cytokine switch. Depletion of natural Tregs abrogated the graft-protecting effect of the TIM-1–specific antibody. Importantly, CD4+CD25+ Tregs obtained from long-term survivors had enhanced regulatory activity as compared with naive CD4+CD25+ Tregs. Consistent with this, TIM-1–specific antibody treatment both preserved Tregs and prevented the expansion of alloreactive effector Th1 cells in an alloreactive TCR transgenic adoptive transfer model. These studies define previously unknown functions of TIM-1 in regulating alloimmune responses in vivo and may provide a novel approach to promoting transplantation tolerance.
Takuya Ueno, Antje Habicht, Michael R. Clarkson, Monica J. Albin, Kazuhiro Yamaura, Olaf Boenisch, Joyce Popoola, Ying Wang, Hideo Yagita, Hisaya Akiba, M. Javeed Ansari, Jaeseok Yang, Laurence A. Turka, David M. Rothstein, Robert F. Padera, Nader Najafian, Mohamed H. Sayegh
Prolongation of cardiac allograft survival by RMT1-10 is associated with a Th1-to-Th2 cytokine switch.